AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)
AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded by Frazier Life Sciences, which led the Series A financing with participation from OrbiMed, Life Sciences at Goldman Sachs…